IL-6 can increase the tumorigenic activity of CSCs by enhancing MFG-E8-induced activity, and the combined blockade of IL-6 and MFG-E8 can significantly reduce the number of primary tumor-derived CSCs, whereas blockade of IL-6 alone or MFG-E8 has only a partial antitumor effect. This evidence concerns the gene IL6 and neoplasm.